Platform|API|Archive|Contact

Humanexa SignalsPharmaceutical Intelligence

FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Pricing
Access
Commercial
Launch Tracking

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

Regulatory
Clinical
Competitive
Markets
M&A Watch
Strategy
Catalyst Tracker

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Asset / Drug

AN4035

Drug and asset intelligence for AN4035 with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 1
Catalysts: 1
Stage: Development stage unavailable

Sponsor company

Adlai Nortye Biopharma Co., Ltd. →

Recent signals(1)

ClinicalJuly 16, 2026

Adlai Nortye initiates trial for AN4035 in RAS-mutated advanced cancers

Adlai Nortye Biopharma is conducting a clinical trial to evaluate the safety and tolerability of AN4035 in patients with advanced solid tumors harboring RAS mutations and high CEACAM5 expression.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(1)

Topline Data

Adlai Nortye Biopharma Co., Ltd. — AN4035

July 16, 2026 · N/A

Indications

No related entities indexed yet.

Therapeutic areas

Oncology · RAS Mutations →

RAS Mutations →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.